tadalafil / Generic mfg. - LARVOL DELTA

Real-world outcomes of tadalafil plus mirabegron combination therapy in men with lower urinary tract symptoms and overactive bladder symptoms: a retrospective cohort study. (PubMed, Aging Male) - "In men with mixed LUTS and prominent storage symptoms, tadalafil plus mirabegron was associated with improvement in overall symptom burden, bladder diary measures, and erectile-function scores without an obvious retention signal. The clinical benefit was clearer for IPSS than for OABSS, so early reassessment is important to identify men who do not improve."

Journal • Real-world evidence • Retrospective data • Overactive Bladder

Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). (PubMed, Aging Male) - "Reports of adverse events (AEs) in male BPH patients receiving AUA guideline-recommended drugs including α-1 blockers (tamsulosin, silodosin, doxazosin, and alfuzosin), 5ARIs (finasteride and dutasteride), and tadalafil were extracted. Sixteen significant AEs were detected, including pollakiuria, gynecomastia, breast pain and so on, with distinct reporting patterns across drug classes. This large-scale pharmacovigilance analysis identified distinct post-marketing safety signals among guideline-recommended pharmacotherapies for BPH, confirming known risks and suggesting potential novel adverse-event signals warranting further investigation."

Adverse events • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia • Pain

Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy. (PubMed, Cancer Med) - "Low NLR was independently associated with improved OS and DFS among patients with HNSCC who received neoadjuvant ICI. These findings suggest the potential utility of the NLR in improving patient selection."

Biomarker • IO biomarker • Journal • Retrospective data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Marked clinical and haemodynamic improvement with sotatercept in severe refractory pulmonary arterial hypertension associated with corrected complex congenital heart disease. (PubMed, Respir Med Case Rep) - "Despite treatment with tadalafil, ambrisentan, and high dose subcutaneous treprostinil, she remained at intermediate-high risk, with WHO-FC III, NT-proBNP 3773 pg/mL and a 6-min walk distance (6MWD) of 480 m. Sotatercept was initiated through an expanded access program. A significant and rapid improvement in haemodynamics and functional capacity was observed after starting sotatercept, in a patient with severe PAH-CHD refractory to maximal therapy. Sotatercept may represent an effective rescue therapy and a potential therapeutic option for complex and severe PAH patients."

Journal • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Diagnostic Uncertainty in a Patient With Late-Onset Hypogonadism-Like Symptoms: A Case Report. (PubMed, Cureus) - "At the patient's request, a trial course of testosterone replacement therapy with testosterone enanthate was initiated, with tadalafil...This case visualizes how entry-point framing, biochemical borderline results, and symptom overlap can prevent diagnostic convergence. It supports a parallel-evaluation diagnostic design that prespecifies competing hypotheses and interprets treatment response as supportive but non-decisive evidence."

Journal • Endocrine Disorders • Erectile Dysfunction • Fatigue • Psychiatry • Urology

PRE-RECORDED: THE PDE5 INHIBITOR TADALAFIL COUNTERACTS AD-SYMPTOMS: MECHANISM OF ACTION IN MUTANT PRESENILIN TRANSFECTED NEURONS (ADPD 2026) - "Td reduces spontaneous activity of neurons in-vitro, and can potentially suppress hyperactive networks to the extent that transfected mPS neurons will not die of hyperactivity. In preliminary experiments we found that indeed Td protects exposed mPS neurons, Our findings indicate a novel route for neuroprotection by showing that Td, through modulation of cGMP selectively protects mPS neurons from damaging hyperactivity."

Alzheimer's Disease • CNS Disorders • APP

REFRACTORY DIGITAL ULCERS AND CHRONIC OSTEOMYELITIS COMPLICATING DIFFUSE SYSTEMIC SCLEROSIS: A REAL-LIFE CASE (SSWC 2026) - "Digital ulcers were refractory to nifedipine 60 mg/day, prompting escalation to alprostadil in 2013 and iloprost in 2016, both initially effective...Sildenafil (up to 150 mg/day, 2024–2025) proved ineffective. Bosentan, initiated in January 2025, was discontinued after re-hospitalization in August 2025 for multiple ulcers and chronic osteomyelitis of the right fifth digit...Osteomyelitis developed in the right second digit in 2019, requiring multiple antibiotic courses (flucloxacillin, amoxicillin–clavula- nate, clindamycin, trimethoprim–sulfamethoxazole) following Staphylococcus aureus isolation, with relapse in 2020 managed with ciprofloxacin...Mycophenolate mofetil (2017–2019) was used for progressive skin fibrosis and NSIP but discontinued due to recurrent osteomyeli- tis. Nintedanib (2021–2024) was initiated for progressive pulmonary fibrosis but withdrawn due to severe diarrhea and weight loss... This case illustrates the complex therapeutic challenges in SSc..."

Clinical • Cardiovascular • Fibrosis • Hepatology • Hypotension • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Musculoskeletal Diseases • Orthopedics • Pneumonia • Primary Biliary Cholangitis • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Venous Ulcer

AIVERT: Investigation of the Effect of the Atherogenic Index on the Therapeutic Response to Tadalafil in Patients With Vascular Erectile Dysfunction (clinicaltrials.gov) - P=N/A | N=132 | Active, not recruiting | Sponsor: Taksim Egitim ve Arastirma Hastanesi

New trial • Dyslipidemia • Erectile Dysfunction • Metabolic Disorders

Comparison of Safety and Efficacy of Avanafil and Tadalafil in the Treatment of Erectile Dysfunction: A Prospective Observational Study. (PubMed, Cureus) - "Conclusion Tadalafil demonstrated slightly better efficacy in improving erectile function compared to Avanafil, although both drugs were effective and well-tolerated. The choice of treatment should consider patient preferences and specific clinical contexts, as both medications offer significant benefits with minimal risk of severe adverse effects. Both PDE-5 inhibitors were effective based on patient-reported outcomes, although objective rigidity was not measured."

Journal • Observational data • Erectile Dysfunction

Outcome of Pediatric Pulmonary Hypertension Patients Requiring ECMO (SCCM 2026) - "100% (31/31) of patients received at least one PAH therapy prior to and during ECMO [31/31 (100%) inhaled nitric oxide or inhaled epoprostenol; 26/31 (84%) sildenafil, tadalafil or riociugat; 18/31 (58%) macitentan, ambrisentan or bosentan; 8/31(26%) selexipag; 10/31(32%) treprostinil. Pediatric PAH is a complex disease due to varied etiologies often requiring multiple medications to effectively manage. Certain subpopulations such as those with single ventricle CHD have higher mortality especially when requiring ECMO. Further study is necessary to determine if earlier identification and management of PAH patients prior to ECMO can improve survival and decrease need for mechanical circulatory support in this high-risk population."

Clinical • Cardiovascular • Heart Failure • Hematological Disorders • Infectious Disease • Pediatrics • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Comparative Effectiveness of Endothelin Receptor Antagonists and PDE-5 Inhibitors in PAH (SCCM 2026) - "Adults carrying an ICD-10 code for PAH (I27.0) who started either ERA monotherapy (bosentan, ambrisentan, macitentan) or PDE5I monotherapy (sildenafil, tadalafil) with no prior prostacyclin or combination therapy were eligible. n this large multicentre, propensity-matched analysis of treatment-naive PAH, ERAs and PDE5Is produced indistinguishable 12-month survival, cardiovascular outcomes, and adverse-event rates. These findings support current guidelines that either class is an acceptable first-line option; choice may therefore be guided by individual comorbidity profiles, side-effect tolerance, and cost rather than expectations of differential efficacy."

HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Pulmonary Arterial Hypertension • Respiratory Diseases

SEVERE PULMONARY ARTERIAL HYPERTENSION AS THE INITIAL MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS/MIXED CONNECTIVE TISSUE DISEASE OVERLAP SYNDROME (ACC 2026) - "Decision-Making: She was treated with inotropic support, intravenous steroids, immunosuppressants and treprostinil...She was maintained on tadalafil, selexipag, rituximab and mycophenolate. PAH can be a manifestation of uncontrolled SLE/MCTD, with notable improvement after treating the flare. Early diagnosis, multidisciplinary approach and multi-modal therapy are key to controlling flares, managing PAH and improving outcomes."

Cardiovascular • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Pulmonary Arterial Hypertension • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus

OFF-LABEL SOTATERCEPT IN HIGH-RISK PULMONARY HYPERTENSION WITH LIVER DISEASE AND LIMITED THERAPEUTIC OPTIONS (ACC 2026) - "Background: Pulmonary arterial hypertension (PAH) and its portopulmonary variant (PoPH) are progressive disorders with high morbidity and limited treatment options, especially in advanced liver disease Case: A 60-year-old woman with severe precapillary PAH from PoPH and COPD overlap (WHO Group 1 & 3), complicated by alcoholic cirrhosis (Child-Pugh A→B) and chronic thrombocytopenia (platelets 70K), remained high risk (REVEAL 2.0 > 9) despite tadalafil, macitentan, and selexipag.She presented with dyspnea and severe precapillary PAH unresponsive to maximal oral therapy; baseline hemodynamics showed markedly elevated pulmonary pressures. Sotatercept delivered meaningful benefit without safety events in advanced PoPH/PAH with cirrhosis and limited options, supporting its potential as an adjunct in complex high-risk PAH and as a bridge optimization pre-transplant"

Cardiovascular • Chronic Obstructive Pulmonary Disease • Fibrosis • Hematological Disorders • Hepatology • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia

PULMONARY VASODILATOR THERAPY IN SCHISTOSOMIASIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: DEMONSTRATED BENEFIT AND NEED FOR FURTHER STUDIES. (ACC 2026) - "He improved with intravenous furosemide and was discharged on bosentan, tadalafil, and torsemide. Sch-PAH represents a delayed yet clinically significant sequela of bilharziasis. Our case illustrates the benefit of targeted PAH therapy in this population and emphasizes the need for prospective studies and registries in endemic regions."

Cardiovascular • Hepatology • Infectious Disease • Pulmonary Arterial Hypertension • Respiratory Diseases

Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label Period. (PubMed, Adv Ther) - P3 | "Long-term treatment with single-tablet combination of macitentan/tadalafil was well tolerated, with no new safety findings identified. Most patients were alive at EOS. Incremental improvements in 6MWD and NT-proBNP observed in the DB with M/T FDC were sustained over 2 years."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • NPPB

Effect of 6-week tadalafil treatment on blood-based biomarkers of neurodegeneration: A post-hoc analysis of a randomized controlled trial. (PubMed, J Alzheimers Dis) - P2 | "Tadalafil reduced plasma levels of biomarkers for amyloid metabolism and astroglial activation in patients with diabetes. Designated clinical trials are warranted to validate these results."

Biomarker • Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • GDF15 • GFAP

Platelet-rich plasma versus daily tadalafil for vasculogenic erectile dysfunction: a randomized controlled trial (AUA 2026) - No abstract available

Clinical • Erectile Dysfunction

Reduction in All-Cause Mortality with Daily Tadalafil Over Three Years: Real-World Evidence (AUA 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence

Tadalafil as anti-inflammatory and antifibrotic agent for improving bladder dynamics in cases of posterior urethral valve (AUA 2026) - No abstract available

Clinical • Pediatrics

A Randomized, Placebo-Controlled Trial Evaluating Tadalafil 5 mg for Management of Early Storage Symptoms and Erectile Dysfunction After HoLEP (AUA 2026) - No abstract available

Clinical • Erectile Dysfunction

Dopamine receptors: Potential therapeutic targets for ischemia-reperfusion injury: A review. (PubMed, Int J Biol Macromol) - "Compounds with high binding affinity, effectiveness and safety, such as piribedil, tadalafil, salvianolic acid A, PD168077, and bromocriptine, have emerged as promising candidates for clinical translation. Concurrently, cutting-edge methods like artificial intelligence offer new perspectives and tools for rational design of drugs targeting these receptors for I/R injury treatment. In-depth exploration of dopamine receptors provides a critical entry point for elucidating the complex pathophysiological mechanisms of I/R injury, while also laying a solid theoretical foundation for development of novel and effective therapeutic strategies."

Journal • Review • Cardiovascular • Reperfusion Injury

Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Assiut University

New P1 trial • Benign Prostatic Hyperplasia

Efficacy and Safety of Tofacitinib Compared to Cyclophosphamide in Early Diffuse Cutaneous Systemic Sclerosis: A Randomized Controlled Trial. (PubMed, Cureus) - P2 | "Tofacitinib demonstrated significant efficacy in reducing skin thickness (mRSS) in early dcSSc, showing both numerical and statistical advantages over cyclophosphamide at 24 weeks, along with a more favorable safety profile. These findings support further evaluation of tofacitinib as a potential therapeutic option in this patient population."

Clinical • Journal • Hematological Disorders • Immunology • Infectious Disease • Nephrology • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis • CRP

Phosphodiesterase inhibitors for the management of lower urinary tract symptoms in men without benign prostatic hyperplasia: a systematic review. (PubMed, Transl Androl Urol) - "Interventions included tadalafil, sildenafil, and combination regimens with tamsulosin or solifenacin. PDE5-Is, especially tadalafil, are effective and well-tolerated for non-BPH LUTS in men, offering advantages beyond urinary symptom relief, including sexual function preservation and pain reduction. These potential effects should be further explored, particularly when erectile dysfunction (ED) or discomfort is present."

Journal • Review • Benign Prostatic Hyperplasia • Erectile Dysfunction • Overactive Bladder • Pain

A Novel Approach to Pulmonary Vasodilator Transitions: Converting Oral Selexipag to Inhaled Treprostinil in Mixed Pulmonary Arterial Hypertension and Covid Associated Interstitial Lung Disease (ISHLT 2026) - "He started on max dose tadalafil, ambrisentan and selexipag. The patient successfully transitioned with this regimen with objective improvement.Summary We present a novel approach of transitioning oral selexipag to inhaled treprostinil in a patient with combined Group 1 and Group 3 PH. Given the risk of oral agents with group 3 PH, our approach to transition was safe and tolerable with clinical improvement."

Cardiovascular • Fibrosis • Hepatology • Immunology • Interstitial Lung Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases